<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00237770</url>
  </required_header>
  <id_info>
    <org_study_id>B3600-R</org_study_id>
    <nct_id>NCT00237770</nct_id>
  </id_info>
  <brief_title>Prevention of Low Blood Pressure in Persons With Tetraplegia</brief_title>
  <official_title>Prevention of Low Blood Pressure in Persons With Tetraplegia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this investigation is to determine the blood pressure response to NOS inhibition,
      with L-NAME, in persons with tetraplegia compared to non-SCI control subjects and to
      establish if blood pressure can be increased while upright in those with tetraplegia. If
      blood pressure is increased with NOS inhibition in persons with tetraplegia, this would
      improve our treatment of the condition of low blood pressure during seated postures in
      individuals with tetraplegia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite disruption of central command of the vasculature during orthostatic maneuvers,
      individuals with tetraplegia are generally able to be seated in an upright position for long
      periods of time without developing symptoms of orthostatic intolerance. It must be
      appreciated however, that orthostatic hypotension may occur unpredictably in persons with
      chronic tetraplegia. This may result in a range of symptoms due to cerebral hypoperfusion
      from mild reduction in mental acuity to loss of consciousness. Nitric oxide (NO) is the most
      potent endogenous vasodilator which is synthesized by the enzyme NO synthase (NOS) and may be
      largely responsible for orthostatic hypotension in individuals with immobilizing conditions.
      Recent evidence suggests an up-regulation of inducible nitric oxide synthases (NOS) activity
      with prolonged exposure to hind limb suspension. The effects of NOS inhibition during
      orthostasis on blood pressure regulation in those with chronic tetraplegia may provide
      insight into effective pharmacological therapy to reduce or prevent pathologic orthostatic
      changes. Treatment with a NOS inhibitor may facilitate the process of mobilization in those
      with acute higher cord lesions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure During Head-up Tilt</measure>
    <time_frame>Average systolic blood pressure during head-up tilt (45 degrees) comparing active drug (L-NAME: 1.0 and 2.0 mg/kg) to placebo.</time_frame>
    <description>Average systolic blood pressure over 45 minutes at 45 degrees of head-up tilt.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hypotension</condition>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control (normal saline) is employed on a separate visit during procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Nitro L-arginine-methylester (L-NAME)</intervention_name>
    <description>A non-specific inhibitor of the nitric oxide synthase enzyme.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Head-up Tilt maneuver</intervention_name>
    <description>Participant will be placed onto tilt table and brought to 15 degrees of head up tilt for 60 minutes (intravenous infusion time). After this time, a progressive increase to 45 degrees will be completed with a 10 degree increase every 5 minutes. Participant will remain at 45 degrees for 45 minutes or until symptom onset.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 65 year olds.

          -  Non-ambulatory Chronic tetraplegia (1 year after acute SCI).

        Exclusion Criteria:

          -  central nervous system disease (other than SCI) e.g., multiple sclerosis, amyotrophic
             lateral sclerosis, syringomyelia, tabes dorsalis;

          -  peripheral neuropathies;

          -  surgical sympathectomy;

          -  coronary heart and/or artery disease;

          -  anemia;

          -  hypertension;

          -  renal function abnormalities;

          -  diabetes mellitus;

          -  pituitary insufficiency;

          -  adrenal insufficiency;

          -  hypothyroidism; and

          -  medications known to affect the cardiovascular system.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Bauman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Bronx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Bronx</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wecht JM, Weir JP, Krothe AH, Spungen AM, Bauman WA. Normalization of supine blood pressure after nitric oxide synthase inhibition in persons with tetraplegia. J Spinal Cord Med. 2007;30(1):5-9.</citation>
    <PMID>17385265</PMID>
  </results_reference>
  <results_reference>
    <citation>Wecht JM, Weir JP, Goldstein DS, Krothe-Petroff A, Spungen AM, Holmes C, Bauman WA. Direct and reflexive effects of nitric oxide synthase inhibition on blood pressure. Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H190-7. Epub 2007 Oct 26.</citation>
    <PMID>17965289</PMID>
  </results_reference>
  <results_reference>
    <citation>Wecht JM, Radulovic M, Lafountaine MF, Rosado-Rivera D, Zhang RL, Bauman WA. Orthostatic responses to nitric oxide synthase inhibition in persons with tetraplegia. Arch Phys Med Rehabil. 2009 Aug;90(8):1428-34. doi: 10.1016/j.apmr.2009.02.004.</citation>
    <PMID>19651280</PMID>
  </results_reference>
  <results_reference>
    <citation>Wecht JM, Radulovic M, Rosado-Rivera D, Zhang RL, LaFountaine MF, Bauman WA. Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia. Arch Phys Med Rehabil. 2011 Nov;92(11):1789-95. doi: 10.1016/j.apmr.2011.03.022. Epub 2011 Jul 16.</citation>
    <PMID>21762873</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2005</study_first_submitted>
  <study_first_submitted_qc>October 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2005</study_first_posted>
  <results_first_submitted>September 24, 2013</results_first_submitted>
  <results_first_submitted_qc>April 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2014</results_first_posted>
  <last_update_submitted>April 23, 2014</last_update_submitted>
  <last_update_submitted_qc>April 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Pressure</keyword>
  <keyword>Cardiovascular Autonomic Control</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>NOS Inhibitor</keyword>
  <keyword>Orthostatic Hypotension</keyword>
  <keyword>Spinal Cord Injury</keyword>
  <keyword>Tetraplegia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Quadriplegia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occured from January 2006 through May 2009; participants were recruited from the James J Peters VA Medical Center and the surrounding community.</recruitment_details>
      <pre_assignment_details>No subject was excluded after enrollment prior to participation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tetraplegic Subjects</title>
          <description>All tetraplegic subjects underwent a head-up tilt maneuver to determine systolic blood pressure responses to placebo L-NAME 1.0 mg/kg and L-NAME 2.0 mg/kg. Subjects with tetraplegia visited the laboratory on 3 separate occasions.</description>
        </group>
        <group group_id="P2">
          <title>Control Subjects</title>
          <description>Systolic blood pressure responses to head-up tilt were determined in non-spinal cord injured control subjects following placebo administration. Control subjects visited the laboratory for 1 visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Individuals With Tetraplegia</title>
          <description>Systolic blood pressure responses to head-up tilt were determined after placebo, L-NAME (1.0 mg/kg) and L-NAME administration (2.0 mg/kg) administration.</description>
        </group>
        <group group_id="B2">
          <title>Able-bodied Controls</title>
          <description>Systolic blood pressure responses to head-up tilt were determined in able-bodied controls following placebo administration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="10"/>
                    <measurement group_id="B2" value="33" spread="9"/>
                    <measurement group_id="B3" value="38" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure During Head-up Tilt</title>
        <description>Average systolic blood pressure over 45 minutes at 45 degrees of head-up tilt.</description>
        <time_frame>Average systolic blood pressure during head-up tilt (45 degrees) comparing active drug (L-NAME: 1.0 and 2.0 mg/kg) to placebo.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tetraplegic Systolic Blood Pressure Responses to Placebo</title>
            <description>Systolic blood pressure responses to head-up tilt were determined after placebo administration in persons with tetraplegia</description>
          </group>
          <group group_id="O2">
            <title>Control Systolic Blood Pressure Responses to Placebo</title>
            <description>Systolic blood pressure responses to head-up tilt were determined in non spinal cord injured controls following placebo administration</description>
          </group>
          <group group_id="O3">
            <title>Tetraplegic Systolic Blood Pressure Responses to L-NAME 1.0 mg</title>
            <description>Systolic blood pressure responses to head-up tilt were determined following administration of L-NAME (1.0 mg/kg)</description>
          </group>
          <group group_id="O4">
            <title>Tetraplegic Systolic Blood Pressure Responses to L-NAME 2.0 mg</title>
            <description>Systolic blood pressure responses during head-up tilt were determined following L-NAME administration (2.0 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure During Head-up Tilt</title>
          <description>Average systolic blood pressure over 45 minutes at 45 degrees of head-up tilt.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.80" spread="20.96"/>
                    <measurement group_id="O2" value="108.10" spread="12.18"/>
                    <measurement group_id="O3" value="112.04" spread="28.01"/>
                    <measurement group_id="O4" value="129.94" spread="26.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tetraplegic Systolic Blood Pressure Responses to Placebo</title>
          <description>Systolic blood pressure responses to head-up tilt were determined after placebo administration in persons with tetraplegia</description>
        </group>
        <group group_id="E2">
          <title>Control Systolic Blood Pressure Responses to Placebo</title>
          <description>Systolic blood pressure responses to head-up tilt were determined in non spinal cord injured controls following placebo administration</description>
        </group>
        <group group_id="E3">
          <title>Tetraplegic Systolic Blood Pressure Responses to L-NAME 1.0 mg</title>
          <description>Systolic blood pressure responses to head-up tilt were determined following administration of L-NAME (1.0 mg/kg)</description>
        </group>
        <group group_id="E4">
          <title>Tetraplegic Systolic Blood Pressure Responses to L-NAME 2.0 mg</title>
          <description>Systolic blood pressure responses during head-up tilt were determined following L-NAME administration (2.0 mg/kg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The small sample of subjects tested and the heterogeneity of spinal lesions.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jill M. Wecht, principal Investigator</name_or_title>
      <organization>James J Peters VA Medical Center</organization>
      <phone>718 584-9000 ext 3122</phone>
      <email>jm.wecht@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

